BioCryst (BCRX) Q2 2026 Earnings Call Transcript
BioCryst (BCRX) discussed its Q2 2026 earnings call, citing ORLADEYO revenue of $158.2M, up 10% year-on-year, and total revenue up 45% excluding the European divestiture. Paid therapy rate rose to 84% from 83% a year earlier. The company said it completed enrollment of the ALPHA-ORBIT pivotal study for navenibart, with top-line data expected in Q3 2027, and reported $113.2M non-GAAP operating profit and $350M+ cash.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 profitability and cash generation based on the revised non-GAAP operating cost guidance, while monitoring ORLADEYO paid rate momentum and pediatric shipment transition details.
Market read
Key new items are ORLADEYO paid rate at 84%, ORLADEYO revenue of $158.2M (+10% YoY on comparable basis), a $55.7M upfront license payment recognized in Q2, and a lowered 2026 non-GAAP operating cost guidance range to $420M-$440M.
What to watch
Execution risk remains around the pediatric launch manufacturing issue and the transition to CareMed as sole-source pharmacy, which could affect shipment timing and near-term revenue recognition.
Background
BioCryst’s Q2 2026 earnings call covers ORLADEYO commercial performance, navenibart pipeline progress, and a strategic shift from internal discovery to external innovation.
Ticker impact
BioCryst reports Q2 2026 revenue growth, ORLADEYO paid rate at 84%, and a lower non-GAAP operating cost guidance range for 2026.
Moderately positive bias for the stock into the next few sessions, with focus on ORLADEYO demand durability and the updated 2026 cost guidance.
The article discloses multiple decision-relevant datapoints: ORLADEYO revenue and paid rate, a manufacturing/pediatric launch step, a new sole-source pharmacy partner, and a revised operating cost guidance range. These are actionable for positioning, though the transcript excerpt does not include full consensus or detailed forward revenue guidance.
Market effects
Reinforces demand and payer-reauthorization resilience for HAE therapies, potentially supporting sentiment toward rare-disease pharma with commercial traction.
Limited direct regional read-through; mentions a European license agreement and former European business adjustments.
Global relevance mainly through the navenibart European license upfront payment and the scale-up plan for pediatric ORLADEYO shipments.
Counterpoint
The transcript emphasizes paid rate and cost savings, but does not provide new, quantified forward revenue guidance beyond the cost range, leaving upside dependent on continued prescription and payer outcomes.
Key entities
- companyBioCryst
US-listed company reporting Q2 2026 results and pipeline/commercial updates for ORLADEYO and navenibart.
- productORLADEYO
HAE therapy whose Q2 revenue and paid rate are discussed, including a new sole-source pharmacy partner for pediatric shipments.
- pipeline_programnavenibart
Investigational long-acting injectable plasma kallikrein inhibitor; pivotal ALPHA-ORBIT enrollment completed and top-line data expected in Q3 2027.
- partnerCareMed
New sole-source pharmacy for ORLADEYO shipments, with pediatric pellets prescriptions shipping from CareMed and 12 and up transitioning during the month.
- partnerNeopharmed Gentili
Counterparty to a navenibart European license agreement referenced for an upfront payment recognized in Q2.
